在黑人和白人个体中,血Aβ42/40的基线水平和纵向变化
Chengjie Xiong1,2, Jingqin Luo3,4, David A Wolk5
1Division of Biostatistics, Washington University, St. Louis, MO, USA.
Nature communications
|July 2, 2024
概括
基于血液的阿尔茨海默病 (AD) 生物标志物可能会改善代表性不足的群体的测试. 这项研究发现,与白人相比,黑人有较低的基线粉样蛋白病理,但与白人相比,积累率相似.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 临床诊断 临床诊断 临床诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于昂贵的方法,限制了不同人群的访问.
- 基于血液的生物标志物为AD检测提供了更容易获得的方法.
- 了解生物标志物流行中的种族差异对于公平的诊断至关重要.
研究的目的:
- 为了比较黑人和白人参与者之间的阿尔茨海默病 (AD) 生物标志物.
- 调查血氨基酸β (Aβ) 水平的种族差异及其与氨基酸β病理学的关联.
- 评估跨种族群体的AD生物标志物的纵向变化.
主要方法:
- 为了了解阿尔茨海默氏症生物标志物的种族研究 (SORTOUT-AB) 招募了324名黑人和1547名白人参与者.
- 使用C2N诊断公司的PrecivityAD测试对Aβ42和Aβ40.0进行血样本分析.
- 随着时间的推移,跟踪了血Aβ42 / 40比率的纵向变化.
主要成果:
- 与白人参与者相比,黑人参与者在基线时表现出更高的平均血Aβ42/40比率.
- 这一差异主要是由于黑人人血Aβ40水平平均较低.
- 尽管基线差异很大,但两组Aβ42/40的纵向变化率相似,表明粉样蛋白积累率相似.
结论:
- 结果与显示黑人较低粉样蛋白病理发病率的研究一致.
- 粉样蛋白的积累似乎在黑人和白人中以相似的速度发生.
- 像Aβ42/40这样的基于血液的生物标志物显示出公平的阿尔茨海默病 (AD) 研究和诊断的潜力.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.3K
相关概念视频
Longitudinal Research
11.9K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
11.9K
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
